In vitro and in vivo antibacterial activities of Q-35, a novel fluoroquinolone.
Q-35, a new fluoroquinolone, was evaluated for its in vitro and in vivo antibacterial activities. In vitro antibacterial activity against gram-positive bacteria was almost equal to that of sparfloxacin or tosufloxacin, but its activity against gram-negative bacteria was 2 times or more lower than that of other quinolones tested. In experimental septicemia, the in vivo activity of Q-35 reflected its in vitro antibacterial activity. In respiratory tract infections with Streptococcus pneumoniae TMS-3 in mice, Q-35 showed a therapeutic effect similar to sparfloxacin and tosufloxacin. Q-35 showed almost the same activity as that of ofloxacin in mice with pyelonephritic infection due to Escherichia coli TMS-3. The peak levels of Q-35 in murine serum, lungs and kidneys after a single oral administration were intermediate compared to those of tested quinolones.
Iwasaki
H
H
Department of Microbiology, Toho University School of Medicine, Tokyo, Japan.
Miyazaki
S
S
Tsuji
A
A
Yamaguchi
K
K
Goto
S
S
D000818:Animals; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000494:pharmacology*; D004195:Disease Models, Animal; D024841:Fluoroquinolones; D006090:Gram-Negative Bacteria / Q000187:drug effects*; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D051379:Mice; D008826:Microbial Sensitivity Tests; D011704:Pyelonephritis / Q000382:microbiology; D015363:Quinolones / Q000008:administration & dosage / Q000494:pharmacology*; D012141:Respiratory Tract Infections / Q000382:microbiology
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; C077155:balofloxacin